Contact Us
Drug Search Results
More Filters [+]

A2B694

Alternative Names: A2B694
Latest Update: 2024-05-29
Latest Update Note: News Article

Product Description

A2B694 is a autologous CAR-T cell candidate from A2 Bio, which acts as a MSLN activator and HLA-A*02 blocker for the treatment of Ovarian, Mesothelioma, Colorectal, Lung and Pancreatic Cancers. (Sourced from: https://www.a2bio.com/our-pipeline/)

Mechanisms of Action: Cell Therapy,HLA

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: A2 Bio
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for A2B694

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Adenocarcinoma|Colorectal Cancer|Mesothelioma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Squamous Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
EVEREST-2

P2

Recruiting

Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Adenocarcinoma|Mesothelioma|Pancreatic Cancer|Ovarian Cancer|Colorectal Cancer

2028-06-01

Recent News Events

Date

Type

Title

05/29/2024

News Article

 A2 Bio Highlights Progress of CAR T-Cell Clinical Programs in Three Poster Presentations during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

05/16/2024

News Article

 A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T

04/24/2024

News Article

 A2 Bio to Highlight Progress of CAR T Clinical Programs in Three Poster Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

11/02/2023

News Article

 A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions